Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5–7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologic ally linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.

However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal Antibodies (mAbs), which are highly commercially successful due to their widespread usage and high cost. Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth.

[b]Check Complete Report @[/b] http://www.marketintelreports.com/report/gbihc376mr/global-immunology-market-to-2022--large-pipeline-and-competitive-market-to-drive-longterm-market-growth

[b]Scope of the Report:[/b]
Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $61.5 billion in 2015 to $74.2 billion in 2022, at a compound annual growth rate of 2.71%.
• What factors are driving the market growth?
• How can the factors limiting growth be overcome?
• There is a very large pharmaceutical pipeline for immunology, consisting of 1,838 products in active development. However, the commercial performance of the products in the late-stage pipeline is expected to be moderate.
• What gaps in the market are being addressed by the most promising of these late-stage pipeline products?
• How does the composition of the pipeline compare with that of the existing market?
• Several key commercially successful products, including Humira (adalimumab) and Remicade, are due to lose patent protection in the forecast period.
• How will this affect their revenues in this period?
• How are their manufacturers, AbbVie and Johnson & Johnson, responding to this?
• The key players in the market, all of which are among the top 20 pharmaceutical companies, are expected to maintain their market lead throughout the forecast period.
• What is driving this continued market dominance?
• Who will the new market players be?

[b]Get Sample Brochure of the Report @[/b] http://www.marketintelreports.com/pdfdownload.php?id=gbihc376mr

[b]Reasons to Buy:[b]
This report will allow you to -
• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis
• Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
• Analyze the immunology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
• Understand the growth in patient epidemiology and market revenues for the immunology market globally and across the key players and product types
• Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological disorders
• Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals

[b]Order a copy of Immunology Market Report @[/b] http://www.marketintelreports.com/purchase.php?id=gbihc376mr

[b]About us:[b]
[b]MarketIntelReports (MIR)[/b] aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.
A group of industry veterans who are well experienced in reputed international consulting firms after identifying the sourcing needs of MNCs for market intelligence, have together started this business savior MarketIntelReports.
MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.
[b]MarketIntelReports[/b] currently has more than 10,000 plus titles and 35+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.

[b]Contact us:[/b]
[b]Mayur S[/b]
Sales Manager
2711 Centerville Road, Suite 400,
Wilmington,
Delaware,
19808
United States
www.marketintelreports.com
[email protected]
Telephone: 1-302-684-6088